vatalanib has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Besse, B; Christoph, D; Eberhardt, WE; Fischer, B; Gauler, TC; Gounant, V; Horsfield, MA; Khalil, A; Krissel, H; Laurent, D; Morgan, B; Nensa, F; Seng, K; Soria, JC; Stattaus, J | 1 |
| Besse, B; Commo, F; Eberhardt, WEE; Fischer, B; Gauler, TC; Gounant, V; Krissel, H; Laurent, D; Mauguen, A; Meric, JB; Overbeck, TR; Soria, JC; Tiainen, M | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Lee, CB; Socinski, MA | 1 |
2 review(s) available for vatalanib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
1 trial(s) available for vatalanib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Phthalazines; Pyridines; Recurrence; Salvage Therapy | 2012 |
2 other study(ies) available for vatalanib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Contrast Media; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Phthalazines; Pyridines; Radiography | 2014 |